Story perspectives

AbbVie, MSD Eye $20B+ Revolution Medicines Acquisition at Conference

1/13/2026

Summary

Story summary

Executives and investors are gathering in San Francisco for the J.P. Morgan Healthcare Conference as reports indicate AbbVie is in advanced talks to acquire Revolution Medicines for more than $20 billion.
MSD is also in discussions to acquire Revolution Medicines, with talks valuing the biotech between $28 billion and $32 billion.
Revolution Medicines' stock rose 33% after takeover rumors.
The conference runs January 12–15, 2025, amid rising M&A activity as global life sciences investments reached $240 billion in 2025.

History

Historical Context

The J.P. Morgan Healthcare Conference in 2020 underscored a significant trend in the biotech sector, with global life sciences investments reaching approximately $180 billion. This surge reflects ongoing consolidation in healthcare, driven by companies like AbbVie and MSD pursuing innovative therapies. The trend builds on earlier M&A activities, such as Siemens Healthineers' acquisition of Varian Medical Systems for $16.4 billion in 2020, reshaping market dynamics.

1 of 2

Story summary

Executives and investors are gathering in San Francisco for the J.P. Morgan Healthcare Conference as reports indicate AbbVie is in advanced talks to acquire Revolution Medicines for more than $20 billion.
MSD is also in discussions to acquire Revolution Medicines, with talks valuing the biotech between $28 billion and $32 billion.
Revolution Medicines' stock rose 33% after takeover rumors.
The conference runs January 12–15, 2025, amid rising M&A activity as global life sciences investments reached $240 billion in 2025.

1 / 2